ResMed Introduces AirFit N30, World’s First Tube-Down Nasal Cradle CPAP Mask
October 21 2019 - 9:00AM
Business Wire
Offers exceptional ease-of-use as the lightest
option in ResMed’s Minimalist mask category
ResMed (NYSE: RMD) (ASX: RMD) today introduced
AirFit N30, the world’s first tube-down nasal cradle CPAP mask with
a front-facing tube – a brand-new option for sleep apnea
treatment.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191021005138/en/
ResMed AirFit N30, tube-down nasal cradle
CPAP mask (Photo: Business Wire)
ResMed’s lightest mask yet, AirFit N30 features an adjustable
elastic headgear, plus a nasal cradle cushion that sits under the
nasal bridge, eliminating soreness in that area. The mask’s curved
cushion is designed to provide a secure seal regardless of how the
wearer sleeps or moves.
Together, these innovations help make starting and staying on
CPAP therapy easier than ever for more of the 936 million people
worldwide living with sleep apnea.
“AirFit N30 is about ease of use, helping people ease into
therapy and addressing the most common pain points for longtime
users,” said Jim Hollingshead, president of ResMed’s Sleep
business. “As the first mask of its kind, AirFit N30 reflects
ResMed’s continued leadership in sleep innovation – the cornerstone
of our company for over 30 years.”
AirFit N30 joins ResMed’s award-winning portfolio of Minimalist
CPAP masks designed to be small, light, and easy to use, including
the popular AirFit P10 nasal pillows mask and AirFit F30
minimal-contact full-face mask.
AirFit N30 is now available in the United States, with other
countries to follow.
About ResMed
At ResMed (NYSE: RMD) (ASX: RMD) we pioneer innovative solutions
that treat and keep people out of the hospital, empowering them to
live healthier, higher-quality lives. Our cloud-connected medical
devices transform care for people with sleep apnea, COPD, and other
chronic diseases. Our comprehensive out-of-hospital software
platforms support the professionals and caregivers who help people
stay healthy in the home or care setting of their choice. By
enabling better care, we improve quality of life, reduce the impact
of chronic disease, and lower costs for consumers and healthcare
systems in more than 120 countries. To learn more, visit ResMed.com
and follow @ResMed.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191021005138/en/
For media Jayme Rubenstein +1 858.836.6798
news@resmed.com
For investors Amy Wakeham +1 858.836.5000
investorrelations@resmed.com
Resmed (ASX:RMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resmed (ASX:RMD)
Historical Stock Chart
From Apr 2023 to Apr 2024